Literature DB >> 24388722

Generalized bullous fixed drug eruption is distinct from Stevens-Johnson syndrome/toxic epidermal necrolysis by immunohistopathological features.

Yung-Tsu Cho1, Jheng-Wei Lin2, Yi-Chun Chen3, Chia-Ying Chang1, Cheng-Hsiang Hsiao4, Wen-Hung Chung2, Chia-Yu Chu5.   

Abstract

BACKGROUND: Generalized bullous fixed drug eruption (GBFDE), a particular form of fixed drug eruption (FDE), is characterized by widespread blisters and erosions and can be confused with Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN).
OBJECTIVE: We sought to analyze specific features of GBFDE and differentiate it from SJS/TEN.
METHODS: We retrospectively studied patients with GBFDE and SJS/TEN during a period of 10 years. GBFDE was defined as typical FDE lesions with blisters involving at least 10% body surface area on at least 3 of 6 different anatomic sites. Clinical presentations; histopathological features; immunohistochemical patterns of cluster-of-differentiation (CD)3, CD4, CD8, CD56, Fas, Fas ligand, granzyme B, perforin, granulysin, and forkhead box P3 (Foxp3); and serum granulysin levels were compared.
RESULTS: Twenty-three cases of GBFDE were collected. Patients with GBFDE had shorter latent periods, less mucosal involvement, more eosinophil infiltration, and dermal melanophages. Lesional infiltrates in GBFDE had more dermal CD4(+) cells including Foxp3(+) regulatory T cells, fewer intraepidermal CD56(+) cells, and fewer intraepidermal granulysin(+) cells. The serum level of granulysin in GBFDE was also significantly lower than in SJS/TEN. LIMITATIONS: The number of cases in this study is small.
CONCLUSION: GBFDE is a distinct disease distinguishable from SJS/TEN by particular features such as granulysin, CD56, and Foxp3 expressions.
Copyright © 2013 American Academy of Dermatology, Inc. Published by Mosby, Inc. All rights reserved.

Entities:  

Keywords:  Stevens-Johnson syndrome; fixed drug eruption; generalized bullous fixed drug eruption; granulysin; regulatory T cells; toxic epidermal necrolysis

Mesh:

Substances:

Year:  2014        PMID: 24388722     DOI: 10.1016/j.jaad.2013.11.015

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN: 0190-9622            Impact factor:   11.527


  17 in total

1.  Contrast-induced generalized bullous fixed drug eruption resembling Stevens-Johnson syndrome.

Authors:  Meredith Gavin; Leigha Sharp; Kendra Walker; Emily Behrens; Russell Akin; Cloyce L Stetson
Journal:  Proc (Bayl Univ Med Cent)       Date:  2019-08-07

Review 2.  Severe Delayed Cutaneous and Systemic Reactions to Drugs: A Global Perspective on the Science and Art of Current Practice.

Authors:  Jonathan Grant Peter; Rannakoe Lehloenya; Sipho Dlamini; Kimberly Risma; Katie D White; Katherine C Konvinse; Elizabeth J Phillips
Journal:  J Allergy Clin Immunol Pract       Date:  2017 May - Jun

Review 3.  Mechanisms of Severe Cutaneous Adverse Reactions: Recent Advances.

Authors:  Teresa Bellón
Journal:  Drug Saf       Date:  2019-08       Impact factor: 5.228

Review 4.  Current Perspectives on Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis.

Authors:  Marianne Lerch; Carlo Mainetti; Benedetta Terziroli Beretta-Piccoli; Thomas Harr
Journal:  Clin Rev Allergy Immunol       Date:  2018-02       Impact factor: 10.817

Review 5.  Bullous Drug Reactions.

Authors:  Maja Mockenhaupt
Journal:  Acta Derm Venereol       Date:  2020-02-12       Impact factor: 3.875

Review 6.  Drug induced exfoliative dermatitis: state of the art.

Authors:  Mona-Rita Yacoub; Alvise Berti; Corrado Campochiaro; Enrico Tombetti; Giuseppe Alvise Ramirez; Andrea Nico; Elisabetta Di Leo; Paola Fantini; Maria Grazia Sabbadini; Eustachio Nettis; Giselda Colombo
Journal:  Clin Mol Allergy       Date:  2016-08-22

Review 7.  Treatments for Severe Cutaneous Adverse Reactions.

Authors:  Yung-Tsu Cho; Chia-Yu Chu
Journal:  J Immunol Res       Date:  2017-12-27       Impact factor: 4.818

Review 8.  Immunohistopathological Findings of Severe Cutaneous Adverse Drug Reactions.

Authors:  Mari Orime
Journal:  J Immunol Res       Date:  2017-10-31       Impact factor: 4.818

9.  Doxycycline Induced Generalized Bullous Fixed Drug Eruption.

Authors:  Indrashis Podder; Somodyuti Chandra; Anupam Das; Ramesh Chandra Gharami
Journal:  Indian J Dermatol       Date:  2016 Jan-Feb       Impact factor: 1.494

10.  Lichenoid drug eruption associated with Bendamustine.

Authors:  Y Kusano; Y Terui; M Yokoyama; K Hatake
Journal:  Blood Cancer J       Date:  2016-06-24       Impact factor: 11.037

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.